Targretin bexarotene capsules: Phase II; marketed to treat refractory cutaneous T cell lymphoma

LGND reported that in a 50-patient, dose-ranging trial lasting 12 weeks with the option

Read the full 147 word article

How to gain access

Continue reading with a
two-week free trial.